Cargando…
Cannabidiol‐induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET
Disulfiram (DSF), an established alcohol‐aversion drug, is a candidate for repurposing in cancer treatment. DSF’s antitumor activity is supported by preclinical studies, case reports, and small clinical trials; however, ongoing clinical trials of advanced‐stage cancer patients encounter variable res...
Autores principales: | Buchtova, Tereza, Skrott, Zdenek, Chroma, Katarina, Rehulka, Jiri, Dzubak, Petr, Hajduch, Marian, Lukac, David, Arampatzis, Stefanos, Bartek, Jiri, Mistrik, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978514/ https://www.ncbi.nlm.nih.gov/pubmed/34632694 http://dx.doi.org/10.1002/1878-0261.13114 |
Ejemplares similares
-
Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
por: Buchtova, Tereza, et al.
Publicado: (2023) -
Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET
por: Kanellis, Dimitris C., et al.
Publicado: (2023) -
Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway
por: Majera, Dusana, et al.
Publicado: (2020) -
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment
por: Chroma, Katarina, et al.
Publicado: (2022) -
Microthermal-induced subcellular-targeted protein damage in cells on plasmonic nanosilver-modified surfaces evokes a two-phase HSP-p97/VCP response
por: Mistrik, Martin, et al.
Publicado: (2021)